Astrazeneca (AZN) Short-term Investments (2009 - 2026)

Astrazeneca's Short-term Investments history runs 18 years deep, the most recent figure standing at $382.0 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 81.9% year-over-year to $382.0 million; the TTM figure through Mar 2026 stood at $382.0 million (up 81.9% YoY), while the FY2025 annual figure was $498.0 million, up 1245.95% from the prior year.
• Short-term Investments was $382.0 million for Q1 2026 at Astrazeneca, down from $498.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $509.0 million in Q2 2025 to a low of -$290.0 million in Q3 2022.
• Historically, Short-term Investments has averaged $169.9 million across 5 years, with a median of $163.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments plunged 422.22% in 2022, then soared 1245.95% in 2025.
• A 5-year view of Short-term Investments shows it stood at $87.0 million in 2022, then surged by 33.33% to $116.0 million in 2023, then tumbled by 68.1% to $37.0 million in 2024, then jumped by 1245.95% to $498.0 million in 2025, then retreated by 23.29% to $382.0 million in 2026.
• The last three Short-term Investments figures came in at $382.0 million (Q1 2026), $498.0 million (Q4 2025), and $502.0 million (Q3 2025), per Business Quant data.